Sign in

You're signed outSign in or to get full access.

Ben Mee

Ben Mee

Research Associate specializing in equity research at Stephens

Milwaukee, WI, US

Ben Mee is a Research Associate specializing in equity research at Stephens, with a focus on the Diagnostics, Genomics, and Proteomics sectors. He covers companies within these fields, leveraging industry expertise gained from roles in Corporate Development and Investor Relations prior to rejoining Stephens. Mee began his career after graduating from the University of Wisconsin-Milwaukee with a B.B.A in Finance and a Certificate in Investment Management, and has since built a profile by providing in-depth company analysis and supporting key investor decisions. His credentials include academic training in finance and investment management, although there are no publicly listed FINRA registrations or securities licenses available for verification.

Ben Mee's questions to VERACYTE (VCYT) leadership

Question · Q3 2025

Ben Mee from Stephens asked about the overlap between urologists targeted for Decipher in prostate cancer and those treating muscle-invasive bladder cancer (MIBC) who would be targets for Veracyte's MRD assay. He also inquired about the trend in ordering patterns for localized prostate cancer patients following the launch of the metastatic offering.

Answer

Chief Commercial Officer John Leite stated there is an exceptionally high overlap, expecting to serve upwards of 70% of the MIBC SAM through existing urologist and oncologist channels. CEO Marc Stapley explained that the metastatic launch added 30,000 addressable patients and helped drive growth across all risk categories for localized disease, with high-risk localized patients showing significant growth, partly influenced by metastatic data and NCCN guidelines.

Ask follow-up questions

Fintool

Fintool can predict VERACYTE logo VCYT's earnings beat/miss a week before the call

Question · Q3 2025

Ben Mee inquired about the overlap of urologists who are Decipher targets for prostate cancer and also treat muscle-invasive bladder cancer (MIBC) for the upcoming MRD assay, and how Decipher's ordering patterns in localized high-risk patients have trended since the metastatic offering launch.

Answer

Chief Commercial Officer John Leite stated there is an exceptionally high overlap, expecting to serve over 70% of the MIBC market through existing urology and oncology channels. CEO Marc Stapley explained that the metastatic offering expanded Decipher's addressable market and has significantly driven growth in the high-risk localized patient segment, demonstrating strong traction across all prostate cancer risk categories.

Ask follow-up questions

Fintool

Fintool can write a report on VERACYTE logo VCYT's next earnings in your company's style and formatting